Compare GTIM & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GTIM | COCH |
|---|---|---|
| Founded | 1987 | 1995 |
| Country | United States | United States |
| Employees | N/A | 47 |
| Industry | Restaurants | Blank Checks |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 49.7M |
| IPO Year | 2013 | N/A |
| Metric | GTIM | COCH |
|---|---|---|
| Price | $1.30 | $0.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 21.8K | ★ 121.9K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $142,315,000.00 | N/A |
| Revenue This Year | N/A | $1.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $43.33 | ★ N/A |
| Revenue Growth | ★ 3.01 | N/A |
| 52 Week Low | $1.10 | $0.36 |
| 52 Week High | $2.09 | $1.89 |
| Indicator | GTIM | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 60.41 | 49.83 |
| Support Level | $1.16 | $0.63 |
| Resistance Level | $1.34 | $0.74 |
| Average True Range (ATR) | 0.04 | 0.04 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 69.23 | 43.71 |
Good Times Restaurants Inc is engaged in developing, owning, operating, and franchising hamburger-oriented drive-through restaurants. It operates through two segments: Good Times Burgers and Frozen Custard restaurants, which operate in the quick-service drive-through dining industry; and Bad Daddy's Burger Bar restaurants, which operate in the full-service upscale casual dining industry. The company generates maximum revenue from the Bad Daddy's Burger Bar restaurants segment. Its menu categories include burgers, chicken, frozen custard; slides and drinks.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.